menu toggle

HTA Quarterly Spring 2024

By AmerisourceBergen

In this edition, we continue our series on preparing for the introduction of European Union (EU) health technology assessment (HTA), consider how United States (US) drug pricing negotiations under the Inflation Reduction Act (IRA) compare with those in countries with an established price negotiation framework, and assess the strengths and limitations of artificial intelligence (AI) tools for literature reviews.

It’s Just…So…Cool – Don’t miss your opportunity for JSC!

The implementing acts on Joint Scientific Consultation (JSC) and Joint Clinical Assessment (JCA) by the European Commission (EC) are eagerly awaited by the industry and national HTA authorities. What are current developments, and how can stakeholders prepare for the EU HTA during the interim period?
Awaiting the JCA implementing acts

Rating the robots: Artificial intelligence for literature reviews

So much scientific evidence, so little time. We assess the performance and capabilities of our newest team member: AI. 

Rating AI for Lit reviews

Apples to apples, or apples to oranges? Comparing the Inflation Reduction Act to drug-pricing programs in other countries

The IRA allows the federal government to negotiate US drug prices for the first time. This article considers how the US system may evolve based on comparison with established price-negotiation processes in Canada, France, and Germany.
Advanced therapies week

Heard on the street

 “Because AstraZeneca has no legitimate claim of entitlement to sell its drugs to the government at any price other than what the government is willing to pay, its due process claim fails as a matter of law.”

U.S. District Judge Colm Connolly wrote in his opinion regarding a lawsuit that challenged the constitutionality of the Inflation Reduction Act (IRA) in a federal court in Delaware, less than  3 weeks after a Texas judge tossed a similar lawsuit by industry lobbying group PhRMA.

Delaware court dismisses AstraZeneca suit challenging IRA

HTA by the numbers


"I think one of the remarkable things about the presentations that I saw today at this conference was that literally 100% of the payers and providers who presented today mentioned AI as a prominent part of their strategy for 2024," said Julie Yoo, general partner at Andreessen Horowitz, while moderating a conference panel discussion on AI.

JPM24: Top trends for payers, providers and health tech companies to watch